Arweave and Injective prices rise as Pullix token sale thrives

February 27, 2024 04:02 PM PST | By Invezz
 Arweave and Injective prices rise as Pullix token sale thrives
Image source: Invezz

Cryptocurrency prices continued soaring this week as retail and institutional investors continued moving to Bitcoin ETFs. This performance may continue because these coins have the momentum and since investors have become greedy. The Fear of Missing Out (FOMO) has moved into the market. This article examines Arweave (AR), Injective (INJ), and Pullix (PLX) and what to expect next.

Pullix token sale continues

Pullix, an upcoming cryptocurrency, is thriving during this crypto bull run as investors look for the next big thing in the crypto industry. The developers have already raised over $8.3 million in the past few months making it one of the best-performing sales of the year. They have sold over 2.1 million tokens representing about 21% of the total tokens scheduled. 

Pullix’s token sale accelerated recently as investors cheered an important Uniswap proposal to reward its token holders. That proposal led many to invest in DEX tokens like dYdX, Synthetix, and PancakeSwap.

It also pushed them to invest in a token like Pullix, which aims to become a leading exchange in the crypto industry. Its main differentiating factor is the fact that Pullix will be at the intersection of a centralised and a decentralized exchange.

By combining the two, the developers aim to remove the challenges that face DEX and CEX exchanges. For example, their aim is to increase liquidity, leading to lower transaction fees for crypto traders. Further, Pullix will have a feature that will reward the PLX token holders and give them discounts.

Pullix is expected to debut its token un Uniswap on March 4th of this year followed by BitMart three days later.

Arweave price forecast

Arweave price

Arweave has emerged as one of the best-performing cryptocurrencies this week. It has soared in the past five days and reached its highest point since May 2022. On the daily chart, we see that the AR token price has flipped important resistance levels into support. For example, it recently crossed the crucial point at $11.62, its highest swing in December.

It has also moved above the important psychological point at $20 this week, signaling that bulls are in control. Along the way, the coin has remained above all moving averages, which is a bullish thing. The MACD and other oscillators have continued rising.

Therefore, it seems like Arweave has a strong momentum and that it could continue rising as buyers target the next psychological point at $25. However, a brief pullback cannot be ruled out as some investors start to take profits.

Injective price prediction

Injective’s (INJ) token price has also done well in the past few days. It has risen in the past five days straight and moved above the descending trendline shown in black. The token has remained above the ascending trendline that connects the lowest levels since January 3rd.

Injective has remained above the 50-day and 25-day moving averages while the MACD indicator has flipped the zero line. The Stochastic Oscillator has moved to the overbought point. 

Most importantly, it has formed a bullish pennant pattern, which is a popular sign of a bullish continuation. Therefore, the INJ token price will likely continue rising as bulls target its all-time high of $45.20. A move above that level will open the possibility of the coin soaring to the psychological point at $50.

Injective price

INJ chart by TradingView

The post Arweave and Injective prices rise as Pullix token sale thrives appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next